| __timestamp | Johnson & Johnson | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 21954000000 | 22570000 |
| Thursday, January 1, 2015 | 21203000000 | 24378000 |
| Friday, January 1, 2016 | 19945000000 | 26621000 |
| Sunday, January 1, 2017 | 21420000000 | 28653000 |
| Monday, January 1, 2018 | 22540000000 | 37734000 |
| Tuesday, January 1, 2019 | 22178000000 | 41884000 |
| Wednesday, January 1, 2020 | 22084000000 | 64435000 |
| Friday, January 1, 2021 | 20118000000 | 57483000 |
| Saturday, January 1, 2022 | 19046000000 | 70062000 |
| Sunday, January 1, 2023 | 20112000000 | 52790000 |
| Monday, January 1, 2024 | 21969000000 |
Igniting the spark of knowledge
In the ever-evolving landscape of the pharmaceutical industry, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry titans: Johnson & Johnson and Ligand Pharmaceuticals Incorporated, from 2014 to 2023.
Johnson & Johnson, a behemoth in the healthcare sector, has consistently maintained high SG&A expenses, averaging around $21 billion annually. Despite a slight dip in 2022, their expenses have remained relatively stable, reflecting their robust operational strategies.
In contrast, Ligand Pharmaceuticals, a smaller player, has seen a significant increase in SG&A expenses, growing by over 200% from 2014 to 2022. This surge underscores their aggressive expansion and investment in growth.
This comparative analysis highlights the diverse strategies employed by these companies in navigating the competitive pharmaceutical landscape.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Johnson & Johnson vs Alnylam Pharmaceuticals, Inc.
Johnson & Johnson and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Exelixis, Inc.
Who Optimizes SG&A Costs Better? Johnson & Johnson or Jazz Pharmaceuticals plc
Comparing SG&A Expenses: GSK plc vs Ligand Pharmaceuticals Incorporated Trends and Insights
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Breaking Down SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Novavax, Inc.
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.